Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Proactive Investors

01:59 EDT 21st April 2018 | BioPortfolio

Here are the most relevant search results for "Proactive Investors" found in our extensive news archives from over 250 global news sources.

More Information about Proactive Investors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Proactive Investors for you to read. Along with our medical data and news we also list Proactive Investors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Proactive Investors Companies for you to search.

Showing News Articles 1–25 of 706 from Proactive Investors

Friday 20th April 2018

Shire: Takeda deadline looms, but will other bidders emerge for in-play £43bn drugs group?

Next week we'll see the colour of Takeda's money. Will rival bidders emerge from the woodwork?

The high holiday for smoking pot: 4/20 festivities planned worldwide

At 4:20pm, thousands around the world will participate in a synchronized smoke-off.

Summit Therapeutics boosted by new DMD drug analysis

It comes as the company and its investors await full results in the third quarter.

Thursday 19th April 2018

Summit Therapeutics accelerating preparatory activities for next DMD study

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) Richard Pye tells Proactive Investors 2017 was a 'landmark' year for them however a number of critical milestones lie ahead of them. Top-line results for ezutromid, a potential breakthrough treatment for sufferers of Duchenne Muscular Dystrophy (DMD), a fatal wasting disease that affects boys are expected to be released in Q3. The read-out fr...

Shire rejects takeover bid from Takeda, said to be in talks with Allergan

Takeda faces a bidding war for Shire following a report that Allergan is in talks to buy the London-listed firm

SkinBioTheraputics “significantly undervalued” despite having demonstrated significant progress

In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

SkinBioTheraputics looks “significantly undervalued” despite having demonstrated significant progress

In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

Shire rejects takeover bid from Japan's Takeda

Takeda has confirmed earlier reports that it had made a cash and stock offer of £46.50 a share for Shire

Motif closes in on approvals, potentially looking for partnership opportunities

US food and drug administration approval isn't there yet, but Motif continues to chug forwards

P&G posts better-than-expected fiscal 3Q results thanks to beauty product sales

Excluding items, the consumer-goods giant earned US$1 per share, which beat Wall Street by two cents

Procter & Gamble acquires German Merck’s consumer health unit for US$4.2bln

P&G will add Merck's vitamins and supplements to its product line

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of successfully culturing the cancer cells from blood samples taken using Parsortix, they have also designed a ...

Summit Therapeutics completes dosing of ezutromid in PhaseOut DMD clinical trial

Initial 24-week results from the 48-week Phase II PhaseOut DMD clinical trial showed a "statistically significant decrease" in muscle inflammation as measured by magnetic resonance spectroscopy transverse relaxation time T2

Immupharma PLC still confident on Lupuzor's future

ImmuPharma PLC (LON:IMM) CEO Dimitri Dimitriou and chairman Tim McCarthy discuss with Proactive Investors the top-line results from their phase III trial of the drug Lupuzor. The data revealed Lupuzor was more effective than the placebo (52.5% versus 44.6%) however because the response rate for those taking the non-active medication plus the “standard of care” was so high the end-point of ...

hVIVO upgraded to Buy by Numis despite CEO resignation

In a note to clients, analysts for the broker said the biotech firm had indicated a more coherent strategy that reflected value despite recent weak share performance

hVIVO upgraded to ‘Buy’ by Numis despite CEO resignation

In a note to clients, analysts for the broker said the biotech firm had indicated a more coherent strategy that reflected value despite recent weak share performance

ANGLE higher as researchers may have found new “high value application” for breakthrough cancer cell capture system

The team from Northwestern University, Chicago, have found a method of extracting and culturing cancer cells outside the body that is reproducible

ValiRx shoots higher, innovation effective at inducing programmed cell death in a wide range of cancers

The company is developing VAL101 in collaboration with academic and commercial partners in Finland, Germany and Denmark

US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer

Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation

Motif Bio to present new Iclaprim safety and efficacy data at top European conference

Motif Bio will tell leading experts at ECCMID 2018 that iclaprim is not only safe and well-tolerated, but that it does far less damage to patients’ kidneys than current treatments

ValiRx PLC innovation effective at inducing programmed cell death in a wide range of cancers

The company is developing VAL101 in collaboration with academic and commercial partners in Finland, Germany and Denmark

OptiBiotix appoints new head of online sales and marketing to develop firm’s web presence

The AIM-listed firm said Steven Riley will lead the development of the Optibiotix online presence as another revenue generating business in its own right

ANGLE PLC: Researchers may have found new “high value application” for breakthrough cancer cell capture system

The team from Northwestern University, Chicago, have found a method of extracting and culturing cancer cells outside the body that is reproducible

ReNeuron wins £1.5mln to fund further development of its hRPC cell therapy candidate

ReNeuron’s human retinal progenitor cell (hRPC) therapy is being developed as a treatment for blindness-causing eye diseases such as retinitis pigmentosa

Wednesday 18th April 2018

Motif Bio evaluating commercialisation options as decision time approaches

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), caught up with Proactive's Andrew Scott as the drug developer gears up for the commercial launch of its next-generation antibiotic. Motif has successfully concluded a second phase III clinical trial on its lead drug, iclaprim and is preparing for regulatory sign-off in America and Europe. It's initiated a rolling submission to the ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks